Gilead, GlobeImmune team up on HBV vaccines

Gilead Sciences ($GILD) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine program. The two developers have inked a worldwide license and collaboration agreement for vaccine products for use in conjunction with Gilead's Viread, which is indicated to treat HIV/AIDS, and other oral therapies for the treatment of chronic HBV infection. Release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.